Drug Profile
MCY M11
Alternative Names: MCY M11Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator MaxCyte; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Developer MaxCyte
- Class Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Late-stage disease, Second-line therapy or greater) in USA (Intraperitoneal, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Mesothelioma(Late-stage disease, Second-line therapy or greater) in USA (Intraperitoneal, Infusion)